Assuming that is the case, the why did they bother with financial restate, hiring investment bankers, continuing on with Andrews, prepping or not to hire IR James Hock and continue to license and deal with the Jan PRs....
Let's assume the process does not work as advertised but partially works with much potential if optimized? Does the patents cover all utilization of ultrasonic cavitation for increasing stem cell populations irregardless of protocol tweaks to optimize???
Per a discussion comment recently here, the number of cells are far superior and even much less viability could yield sufficient stem cells for treatment.
Have they been optimizing the protocols for the past 6 months and is the uncertain outcome why this is "stagnant"???
News 
Market Data 
Discover 
